Podcasts about Regeneron Pharmaceuticals

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QPE865. CME/MOC/AAPA credit will be available until June 20, 2026.Advancing Care for Chronic Spontaneous Urticaria: Navigating an Evolving Treatment Landscape for Optimal Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

Just when it looked like 23andMe was selling to Regeneron Pharmaceuticals, founder Anne Wojcicki placed a bid through her new nonprofit in an attempt to win it back at the eleventh hour. Lila MacLellan, Senior Writer at Fortune, joins David to discuss Wojcicki's leadership style, and what the new version of 23andMe might look like under her control. Later, Alexi Horowitz-Ghazi of NPR's Planet Money shares what happens to people's sensitive health data when the company holding that information files for bankruptcy — and how consumers can protect themselves. Be the first to know about Wondery's newest podcasts, curated recommendations, and more! Sign up now at https://wondery.fm/wonderynewsletterListen to Business Wars on the Wondery App or wherever you get your podcasts. Experience all episodes ad-free and be the first to binge the newest season. Unlock exclusive early access by joining Wondery+ in the Wondery App or on Apple Podcasts. Start your free trial today by visiting wondery.com/links/business-wars/ now.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The 23andMe saga continues, the Trump Organization announces phones and cell plans, and beloved Anker has a recall. After Apple's WWDC and our special episode last week, there's plenty of tech news to get caught up on this week. Time to tech better! Watch on YouTube! - Notnerd.com and Notpicks.com INTRO (00:00) Dave Plays Games - iPhone can be used as a Nintendo Switch 2 webcam (05:00) WWDC Followup (08:55) MAIN TOPIC: 23andWho (15:05) 23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million 23andMe says 15% of customers asked to delete their genetic data since bankruptcy DAVE'S PRO-TIP OF THE WEEK:  Sort by recently added in photos plus more. (19:20) JUST THE HEADLINES: (26:25) An experimental new dating site matches singles based on their browser histories Barbie goes AI as Mattel teams with OpenAI to reinvent playtime with artificial intelligence China shuts down AI tools during nationwide college exams Volvo debuts new Internet of Things seatbelt design Amazon doubles Prime Video ads to 6 minutes per hour The IRS tax filing software TurboTax is trying to kill just got open sourced Scientists in Japan develop plastic that dissolves in seawater within hours TAKES: Trump Mobile launches: What to know about the T1 Phone, 47 calling and data plan (29:50) Disney, NBCU sue Midjourney over copyright infringement (35:20) Microsoft Patch Tuesday, June 2025 Edition (37:00) Anker is recalling over 1.1 million power banks due to fire and burn risks (40:45) Meta found a new way to track android users covertly via Facebook & Instagram (44:05) BONUS ODD TAKE: Old iPhone Simulator (50:25) PICKS OF THE WEEK: Dave: Nintendo Switch 2 (52:50) Nate: Re-pick Amazon Basics 50-inch Lightweight Portable Camera Mount Tripod Stand with Bag, for Travel Photography, Champagne - https://www.notnerd.com/episode-124-stealing-the-spotlight/ (54:50) RAMAZON PURCHASE - Giveaway! (59:25)

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 27, 2026.Planting Roots for Next-Gen Bispecific Antibodies in Hematologic Cancers: Collaborative Principles to Extend the Reach of Immunotherapy in Myeloma and Lymphoma In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 27, 2026.Planting Roots for Next-Gen Bispecific Antibodies in Hematologic Cancers: Collaborative Principles to Extend the Reach of Immunotherapy in Myeloma and Lymphoma In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 27, 2026.Planting Roots for Next-Gen Bispecific Antibodies in Hematologic Cancers: Collaborative Principles to Extend the Reach of Immunotherapy in Myeloma and Lymphoma In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 27, 2026.Planting Roots for Next-Gen Bispecific Antibodies in Hematologic Cancers: Collaborative Principles to Extend the Reach of Immunotherapy in Myeloma and Lymphoma In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 27, 2026.Planting Roots for Next-Gen Bispecific Antibodies in Hematologic Cancers: Collaborative Principles to Extend the Reach of Immunotherapy in Myeloma and Lymphoma In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 27, 2026.Planting Roots for Next-Gen Bispecific Antibodies in Hematologic Cancers: Collaborative Principles to Extend the Reach of Immunotherapy in Myeloma and Lymphoma In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/copd-inflammation-exacerbations-your-questions-answered-10143SummaryRejoin the conversation on COPD, inflammation, and new and emerging agents as two of our expert faculty come together to answer your top questions. Questions submitted from the recent Conversations in Primary Care live virtual symposia guide the discussion as we dig a bit deeper on type 2 inflammation, changes in COPD management, and new and emerging agents – including recently approved biologic agents – for COPD.Learning ObjectivesAt the conclusion of this activity, participants should be better able to:Review the relationship between inflammation, exacerbation, and disease progression in COPD, noting different inflammatory endotypes of patients with COPDDiscuss recent evidence surrounding the use of biologic agents in the management of patients with COPD and type 2 inflammationIntegrate current guidelines with clinical data on new and emerging agents for the management of COPD, distinguishing patients with and without markers of type 2 inflammationThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Summary of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

First Time Homebuyers Hit a Record Low With the high cost of housing and higher interest rates, people trying to get their first home dropped to a record low around 23% in 2024. The average age of the first-time homebuyer has increased 10 years over the historical average to 38 years old. The median income is now $97,000 and the first-time home buyers are coming up with an average down payment of 9% of the value of the home. Many of these young buyers are using FHA loans, which require a very small down payment and according to research roughly 30% of all FHA mortgages have a debt service ratio of over 50%. This means more than half of these buyers' incomes is going toward servicing debt. This could be a hard pill to swallow for young buyers with not much money left over for luxuries like vacations and new cars. However, if when they buy the home, they understand that if they really tighten their belts for the next three to four years, they will probably be fine. New home builders are doing what they can to try and get rid of the largest inventory of unsold homes on their lots since 2009. The median price of a new home is currently less than one percent higher than the median price of existing properties, which historically has seen a 17% premium. The home builders are using profits from their homes to buy down mortgages. Even though the 30-year mortgage was recently around 6.8%, home builders can buy these mortgages down which led buyers of new homes to a rate around 5%. Buying down these rates has cost home builders about 8% of the purchase price of the home. This reduces their profits but better than the alternative of sitting on unsold homes with a carrying cost for the builder. I don't see this situation getting better anytime soon because I'm not looking for a large decrease in mortgage rates and incomes over the next year will probably increase somewhere around 3 to 4%. We continue to believe the rapid increase in the price of homes over the last few years will not last and it will now take some time to get back to normal market. Maybe we will see a better real estate market in 2027 or 2028.   Is Bitcoin coming to your 401k? I have been concerned with bitcoin and crypto as a whole for several years for many reasons including fraud, illicit activity, and the fact that there is really no way to derive an intrinsic value for it since there is no earnings, cash flow, or anything really backing the asset class. I was disappointed to see the current Labor Department removed language that cautioned employers to exercise “extreme care” before making crypto and related investments available to their workers. They cited “serious concerns” about the prudence of exposing investors' retirement savings to crypto given “significant risks of fraud, theft, and loss.” While this isn't necessarily a full-on endorsement for placing crypto in 401k plans, it definitely seems like the administration is continuing on its path to try and normalize crypto as an established asset class. Even with this change in language I would be surprised to see a huge surge in cryptocurrencies within 401k plans. Ultimately, ERISA bestows a fiduciary duty on employers and company officials overseeing 401k investments and that means legally employers must put the best interests of 401(k) investors first and act prudently when choosing which investments to offer (or not offer). Given the extreme volatility within crypto I believe it would be a huge risk for these companies to offer it as it could open them up to lawsuits if there are major declines. We'll have to see what other changes are made as time progresses, but I don't believe crypto has any place within a 401k plan at this time.   Inflation report shows continued progress The personal consumption expenditures price index, which is also known as PCE and is the Federal Reserve's key inflation measure, showed an annual increase of just 2.1%. Core PCE, which excludes food and energy, showed a gain of 2.5%. Both results were 0.1% below their respective estimates. Overall, inflation has continued to cool and is now quite close to the Fed's 2% target. The question that remains is how will tariffs ultimately impact inflation? An economist from Pantheon Macroeconomics said that he believed core PCE would peak later this year between 3.0% and 3.5%, if the current mix of tariffs remained in place. I would say it is difficult to forecast the tariff impact since we don't know what will ultimately be passed on to the end consumer. It will definitely be interesting to see what numbers look like in the coming months, but ultimately, I believe most of the concerns around inflation are overblown and even if the rate for PCE is around 3%, I don't see that as being problematic for the economy.     Financial Planning: What it Means to be an Accredited Investor An accredited investor is someone who meets specific income or net worth thresholds—such as earning over $200,000 annually ($300,000 with a spouse) or having over $1 million in net worth excluding their home—and is allowed to invest in private securities offerings not registered with the SEC. These investments, which include private REITS, private equity, hedge funds, and startups, often promise high returns but carry significant risks such as illiquidity, limited transparency, and the potential for total loss. While many of these offerings are only available through fiduciary advisors—who are legally obligated to act in their clients' best interest—investors must still exercise caution. Fiduciary duty applies only in certain contexts (such as investment advice) and may not extend to related areas like insurance or commission-based products. Additionally, what qualifies as “acting in your best interest” is often subjective and open to interpretation. Working with a fiduciary does not guarantee protection, and investors should remain vigilant, ask questions, and independently evaluate any recommendation. Also, private investments aren't necessary better than public investments, so just because you qualify as an accredited investor doesn't mean you should be investing in private securities.   Companies Discussed: Regeneron Pharmaceuticals, Inc. (REGN), Intuit Inc. (INTU), Target Corporation (TGT) & Toll Brothers, Inc. (TOL)

The House Budget Committee moves forward a tax bill with significant cuts to Medicaid. Pennsylvania's governor calls for more oversight of private equity healthcare deals following the closure of Crozer Health. And, Regeneron Pharmaceuticals buys 23andme's assets for $256 million. Those stories and more coming up on today's episode of the Gist Healthcare podcast. Hosted on Acast. See acast.com/privacy for more information.

Microsoft Build and Google I/O, each company's annual developer conference, are taking place this week. As with most AI news these days, we can't cover everything they announced, nor would we want to. But what does this runaway train of AI progress mean for you? Watch on YouTube! - Notnerd.com and Notpicks.com INTRO (00:00) File your Siri lawsuit claim (04:05) Fortnite returns to the App Store for iPhone and iPad (06:05) MAIN TOPIC: Microsoft Build and Google I/O (12:10) Microsoft Build 2025: news and announcements from the developer conference Everything Google announced at I/O 2025: Gemini, Search, Android, and more DAVE'S PRO-TIP OF THE WEEK:  Safari remove distracting items (36:25) JUST THE HEADLINES: (44:40) The top fell off Australia's first orbital-class rocket, delaying its launch HBO Max lives! Max to change its name back after 2 years CERN gears up to ship antimatter across Europe Chinese ‘kill switches' found hidden in US solar farms NASA engineers fixed some thrusters on Voyager 1 from 15 billion miles away Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million InventWood is about to mass-produce wood that's stronger than steel TAKES: Airbnb introduces services (46:45) Top tier Adobe Creative Cloud plan increasing to $800 per year (49:35) Microsoft extends Office app support on Windows 10 to 2028 (53:15) KrebsOnSecurity Hit With Near-Record 6.3 Tbps DDoS  (54:35) BONUS ODD TAKE: 10,000 Drum Machines (57:05) PICKS OF THE WEEK: Dave: Zhiyun Molus x100 RGB Cam Mackey (01:00:55) Nate: SMALLRIG Camera Cage for Sony ZV-1 II/ZV-1F / ZV-1 Camera, with Silicone Gel Grip, Cold Shoe Mount (01:06:15) RAMAZON PURCHASE - Giveaway! (1:08:30)

Rich welcomes Dr. Sebastian Gorka, deputy assistant to President Trump and senior director for counter terrorism at the National Security Council, to talk about the 'Golden Dome' defense system and other matters of national security. Next, Regeneron Pharmaceuticals is buying 23andMe for $256 million; we get reaction from Dr. Steven Quay, founder of Atossa Therapeutics. We also talk tariffs and China with Kerry Lutz, best-selling author of host of Financial Survival Network. Plus, Dr. Elaine Healy, whom you may recall as a COVID whistleblower, tells why she has informed Delaware authorities of the possible elder abuse of former President Joe Biden. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The House Budget Committee advanced President Trump's multi trillion-dollar domestic policy package Sunday night, just two days after conservatives voted to reject it. CNBC's Eamon Javers reports on this and President Trump's clash with Walmart over tariff-driven price hikes. Walter Isaacson, biographer and Tulane professor, discusses gene editing breakthroughs and biotech innovation amid federal funding cuts, as well as the White House's relationship with corporate America's leaders. Then, Business Roundtable CEO Josh Bolten weighs in on how CEOs are responding to Trump-era policies, including the President's trade agenda. Plus, Regeneron Pharmaceuticals has announced plans to acquire most of 23andMe's assets for $256 million. Walter Issacson       18:22Josh Bolten          28:39 In this episode:Eamon Javers, @EamonJaversWalter Isaacson, @WalterIsaacsonBecky Quick, @BeckyQuickAndrew Ross Sorkin, @andrewrsorkinZach Vallese, @zachvallese

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NFR865. CME/MOC/CC/AAPA/IPCE credit will be available until May 25, 2026.Biologic Therapy for CRSwNP: Exploring the Advanced Practice Provider's Role in Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NFR865. CME/MOC/CC/AAPA/IPCE credit will be available until May 25, 2026.Biologic Therapy for CRSwNP: Exploring the Advanced Practice Provider's Role in Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NFR865. CME/MOC/CC/AAPA/IPCE credit will be available until May 25, 2026.Biologic Therapy for CRSwNP: Exploring the Advanced Practice Provider's Role in Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NFR865. CME/MOC/CC/AAPA/IPCE credit will be available until May 25, 2026.Biologic Therapy for CRSwNP: Exploring the Advanced Practice Provider's Role in Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NFR865. CME/MOC/CC/AAPA/IPCE credit will be available until May 25, 2026.Biologic Therapy for CRSwNP: Exploring the Advanced Practice Provider's Role in Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NFR865. CME/MOC/CC/AAPA/IPCE credit will be available until May 25, 2026.Biologic Therapy for CRSwNP: Exploring the Advanced Practice Provider's Role in Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Philipp Vetter und Holger Zschäpitz über zwei gelungene Börsengänge, einen weiteren Tiefschlag für Bayer und einen Absturz bei Tui. Außerdem geht es um Etoro, Pfisterer Holding, Super Micro, AMD, Nvidia, Coreweave, Cisco, Eon, Daimler Truck, Brenntag, Renk, Hapag Lloyd, Baidu, WeRide, Uber, General Motors, Mercedes-Benz, BMW, Volkswagen, Pony.AI, Momenta Technology, Tesla, Alphabet, Archer Aviation, Marvell Technology, Broadcom, The Trade Desk, Datadog, MongoDB, Adobe, Diamondback Energy, Regeneron Pharmaceuticals, Warner Bros Discovery, Rheinmetall, Siemens Energy. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Great Stock Picks in 18 New Articles! Features analyst stock picks in sustainable technology, healthcare, fashion, jewelry, manufacturing, and more. By Ron Robins, MBA Transcript & Links, Episode 153, May 16, 2025 Hello, Ron Robins here. Welcome to my podcast episode 153, published May 16, 2025, titled “Great Stock Picks in 18 New Articles!” So, this podcast is presented by Investing for the Soul. Investingforthesoul.com is your site for vital global ethical and sustainable investing mentoring, news, commentary, information, and resources. Remember that you can find a full transcript and links to content, including stock symbols and bonus material, on this episode's podcast page at investingforthesoul.com/podcasts. Also, a reminder. I do not evaluate any of the stocks or funds mentioned in these podcasts, and I don't receive any compensation from anyone covered in these podcasts. Furthermore, I will reveal any investments I have in the investments mentioned herein. Additionally, please visit the podcast's webpage for links to the articles and additional company and stock information. I have a great crop of 19 articles for you in this podcast! ------------------------------------------------------------- Great Stock Picks in 18 New Articles! (1) The first article I'm reviewing appeared on insidermonkey.com. It's titled 11 Cheap ESG Stocks to Buy According to Hedge Funds by Rameen Kasana. Ms. Kasana employs fascinating methodology to arrive at her stock selection. Here are some quotes on her process and, importantly, her stock picks. “We have compiled a list of 11 companies ranked by Sustainalytics (by Morningstar) in its recent ESG Top-Rated Companies report. From the report, we identified companies with a forward P/E less than 15, extracted from FINVIZ. From there, we picked companies with the highest number of hedge fund investors, as per Insider Monkey's database of Q4 2024. 11. Flex Ltd. (NASDAQ:FLEX) Number of Hedge funds holding: 52 Flex Ltd. operates as a contract manufacturing company that offers design, manufacturing, and product management solutions to electronic and technology companies. While the Flex Agility Solutions (FAS) segment is centered on communications, consumer devices, and lifestyle, the Flex Reliability Solutions (FRS) segment encompasses markets like Automotive, Health Solutions, and Industrial. 10. Seagate Technology Holdings plc (NASDAQ:STX) Hedge funds holding: 52 Seagate Technology Holdings plc is a leading provider of hard disk drives for data storage for both enterprise and consumer markets. With a presence in Singapore, the United States, the Netherlands, and internationally, the core offerings of the company include mass capacity storage products, legacy applications, and the Lyve edge-to-cloud mass capacity platform. 9. Crown Holdings, Inc. (NYSE:CCK) Hedge funds holding: 53 Crown Holdings is a global packaging powerhouse operating through the Americas Beverage, European Beverage, Asia Pacific, and Transit Packaging segments. Founded in 1892, the company manufactures and markets recyclable aluminum beverage and non-beverage cans, steel crowns, glass bottles, ends, and closures. From food to household and industrial industries, the company serves a wide clientele. 8. Tapestry, Inc. (NYSE:TPR) Hedge funds holding: 57 Tapestry, Inc. is a global house of leading fashion brands, particularly Coach, Kate Spade New York, and Stuart Weitzman. Headquartered in New York, the company offers its products directly and indirectly via wholesale and licensing businesses. The enterprise claims to use its strengths to empower communities and make the fashion industry more sustainable, equitable, inclusive, and diverse. 7. Hewlett Packard Enterprise Company (NYSE:HPE) Hedge funds holding: 66 Hewlett Packard Enterprise Company is a U.S.-based leading information technology company that provides smart solutions and cloud-based services. The core offerings of the company include servers, storage devices, networking products, software, IT support, and customized financial solutions. From retailers and distribution partners to direct sales management, independent software vendors, and equipment manufacturers, the tech giant markets through a range of experts. 6. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Hedge funds holding: 68 Regeneron Pharmaceuticals is a leading biotechnology company serving people living with eye disease, cardiovascular disease, cancer, and inflammation. Headquartered in New York, the company develops and markets life-changing medicines for people with severe illnesses. Driven by its ‘Doing Well by Doing Good' philosophy, Regeneron Pharmaceuticals facilitates a culture that promotes integrity and builds sustainable communities. 5. The Cigna Group (NYSE:CI) Hedge funds holding: 72 The Cigna Group is a global health company providing insurance and related products. With two main segments: Evernorth Health Services and Cigna Healthcare, it has a vast offering including coordinated and point solution health services, and pharma-related care. Based in Connecticut. 4. Elevance Health, Inc. (NYSE:ELV) Hedge funds holding: 73 Elevance Health is a U.S.-based health insurer that operates through four segments, including Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. Incepted in 2001, the company also provides pharmaceutical services, managed care services, health products, and behavioral health management, among others. 3. QUALCOMM Incorporated (NASDAQ:QCOM) Hedge funds holding: 79 QUALCOMM Incorporated headquartered in California, is a digital telecommunications provider, operating through three segments, namely Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). With a market capitalization of $162.449 billion, the company is recognized as the 158th most trusted company in America by Forbes. The core values of the company include empowering people, transforming communities, and protecting the planet. 2. Cisco Systems, Inc. (NASDAQ:CSCO) Hedge funds holding: 84 Cisco Systems is a U.S.-based firm that offers information technology and networking services. Incepted in 1984, the company also offers network security and access management services. Cisco delivers its products and services directly and indirectly through system integrators, service providers, and other distributors. 1. Western Digital Corporation (NYSE:WDC) Hedge funds holding: 85 Western Digital Corporation is a California-based global leader in the hard disk drive market. While providing data storage solutions, the giant is fully dedicated to preserving and protecting the planet. The company's initiatives revolve around reducing, recycling, reusing, and saving for the generations to come.” End quotes. ------------------------------------------------------------- Great Stock Picks in 18 New Articles! (2) The second article comes to us from the renowned Morningstar site. It's titled 2 Undervalued Automation Companies for Sustainable Investors. It's by Liz Angeles. Now, some quotes from her article. “The Morningstar Rating compares a stock's current price with Morningstar's estimate of its fair value, which is based on the present value of the company's future cash flow. A 4-star stock is undervalued, and a 5-star stock is significantly undervalued. 1) Sika Group (SKFOF) Established in 1910, Switzerland-based Sika produces specialty chemicals primarily used by the construction sector (85% of sales). Its products are mainly used for bonding, sealing, reinforcing, and protecting in the construction and automotive industries. Approximately 70% of its products have a positive impact on sustainability for customers. Sika has a global manufacturing footprint of more than 400 factories spread across over 100 countries. Price/Quantitative Fair Value: 0.89 Quantitative Morningstar Rating: ★★★★★ ESG Risk Rating Assessment: Medium Sector: Basic Materials 2) Zebra Technologies (ZBRA) Zebra Technologies is a leading provider of automatic identification and data capture technology to enterprises. Its solutions include barcode printers and scanners, mobile computers, and workflow optimization software. The firm primarily serves the retail, transportation logistics, manufacturing, and healthcare markets, designing custom solutions to improve efficiency for its customers. Analyst: William Kerwin, CFA Price/Fair Value: 0.75 Morningstar Rating: ★★★★ ESG Risk Rating Assessment: Negligible Sector: Technology” End quotes. ------------------------------------------------------------- Great Stock Picks in 18 New Articles! (3) This third article has a perspective that many investors concur with and posits it regarding Netflix. The title of the article is Possible Stock Split? This Stock Has Surged 284% Since 2023 -- Here's Why You Shouldn't Wait to Buy It. It's by Adam Levy of The Motley Fool and found on finance.yahoo.com. Here are a few brief quotes from Mr. Levy's article. “But enacting a stock split can be a very strong signal from management to investors. Management will usually initiate a stock split after a run-up in the price of the stock. When it announces a split, it's suggesting the current run-up in price is justified and that it expects the price to continue climbing. On the other hand, the confidence boost provided by a stock split will only go as far as the company's next earnings report or news item. If the fundamentals of the business are no good, or the stock has gotten ahead of itself, it doesn't make sense to buy it just because of a stock-split announcement. One stock I've had my eye on looks poised for a stock split this year. It's up 284% since the start of 2023, and investors have an opportunity to get in now, whether management announces a split in the near future or not. [That stock is] Netflix (Nasdaq: NFLX).” End quotes. ------------------------------------------------------------- Great Stock Picks in 18 New Articles! (4) The fourth article I'm posting appeared recently on one of the finest sites I know. That is corporateknights.com. The article's title is Pandora's big bet on sustainability pays off. It's by Naomi Buck. Here are a few quotes from that article. “Pandora (PNDORA.CO) According to those who study consumer habits, millennials and Gen Zs are looking for two things when they go shopping: sustainability and individuality. One jewellery company is capturing hearts and wallets by offering both. Pandora, launched as a family-run jewellery shop in Copenhagen in 1982, has grown to become the world's largest jewellery maker, by pieces sold. And unlike much of its industry in recent years, Pandora's star is rising. As competitors like Tiffany and Signet see diminishing returns, Pandora ended 2024 with 31.7 billion krone (US$4.5 billion) in annual revenue, representing 13% organic growth… In 2019, following several years of declining sales, Pandora embarked on a new strategy: to expand its product line beyond the luxury charm bracelets for which it had become famous and go all in on sustainability. It established three new priorities: to decarbonize, push circularity and promote a more diverse corporate culture. While sustainability may be front of mind for younger buyers, [Pandora CEO Alexander] Lacik admits that the average jewellery shopper is looking primarily at design and price. But even if customers weren't clamouring for it, Pandora's sustainability push has proven a sound business decision; according to its 2024 annual report, the company has grown by 45% since 2019. No doubt, others in the industry are watching with interest.” End quotes. Also, see this New York Times article on Pandora How the World's Largest Jeweler Is Surviving the Trade War. It's by Eshe Nelson. ------------------------------------------------------------- Great Stock Picks in 18 New Articles! (5) This fifth article was also posted on corporateknights.com with the same author as the previous article, Naomi Buck. Its title is Italy's ERG proves you can trade oil for renewables and win. Again, here are a few quotes from the article. “ERG (ERG.MI) In 2008, the Italian oil company ERG faced a crossroads. Having sold its 49% stake in a Sicilian refinery to Russian oil giant Lukoil just before the markets crashed, it had cash to burn. And it had a fundamental choice to make… By 2013, ERG had become Italy's leading producer of wind energy. It now has installed capacity in the United Kingdom, Germany, France, Poland, Romania, Bulgaria and Sweden, making it one of the continent's top 10 wind companies. It also owns major solar installations in Italy, Spain, France and the United States.  ERG's wholesale transition from black to green took little over a decade, and with it the company redefined itself: no longer responding to Italy's demand for oil, it sees itself – in its own words – ‘inspiring change to power the future.'” End quotes. ------------------------------------------------------------- More articles of interest for ethical and sustainable investors from around the world 1. Title: Top 3 Mutual Funds to Invest in India (2025) on shariahsecurities.com. By Shariah Securities. 2. Title: Top Halal Mutual Funds For 2025 on tradersunion.com. By Alamin Morshed. 3. Title: Investing in Green Bonds: Your Complete Guide on fool.com. By Benjamin Locke. 4. Title: Making sense of a rough quarter for ESG funds on ft.com. By Simon Mundy. 5. Title: 11 Most Carbon-Friendly AI Companies Leading the Sustainable Technology Revolution on theimpactinvestor.com. By Kyle Kroeger. 6. Title: Simon Property Group a Top Socially Responsible Dividend Stock With 5.3% Yield (SPG) on nasdaq.com. By BNK Invest. 7. Title: How some companies are rapidly adapting to the energy transition on corporateknights.com. By Naomi Buck. 8. Title: 3 Large-Cap Stocks with Solid Fundamentals on finance.yahoo.com. By Kayode Omotosho. 9. Title: Understanding ESG scores and their impact on investment choices on equities.com. By Shane Neagle. 10. Title: ADP Named A Top Socially Responsible Dividend Stock on theonlineinvestor.com. By Online Investor Staff. 11. Title: The Best AI ETFs to Buy in 2025 on moneymagpie.com. By Ruby Layram. 12. Title: 13 Best AI Stocks to Buy Under $10 on insidermonkey.com. By Abdul Rahman. ------------------------------------------------------------- Ending Comment These are my top news stories with their stock and fund tips for this podcast, “Great Stock Picks in 18 New Articles!” Please click the like and subscribe buttons wherever you download or listen to this podcast. That helps bring these podcasts to others like you. And please click the share buttons to share this podcast with your friends and family. Let's promote ethical and sustainable investing as a force for hope and prosperity in these troubled times! Contact me if you have any questions. Thank you for listening. I'll talk to you next on May 30th. Bye for now.   © 2025 Ron Robins, Investing for the Soul

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Bayer has announced a restructuring that will result in 2,000 job cuts and a reduction in management layers. CEO Bill Anderson believes Trump's most favored nations policy could provide an opportunity for European countries to contribute more to biopharma innovation. Galapagos has abandoned plans for a spinout and cell therapy, causing a stir in the industry. Trump's most favored nation policy has led to a sell-off of PBMs, but analysts believe it may not have a significant impact without further congressional action. Sino Biological offers solutions for autoimmune diseases, with reagents for nearly 50 different conditions. In other news, CMS is preparing for a new cycle of drug negotiations, Azafaros has raised $150 million for rare neuro-metabolic diseases, and Roche's Genentech is investing $700 million in a North Carolina plant. 10x Genomics has cut 8% of its workforce, and there are upcoming webinars on biotech downturns and AI in life science R&D. Job opportunities include positions at 4D Molecular Therapeutics, Takeda, and Regeneron Pharmaceuticals.

Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care.  Uncover: ·      The importance of patient phenotyping: How can biomarkers and imaging improve asthma management? ·      Mucus plugging and airflow obstruction: What does the latest research reveal? ·      Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling? ·      The role of imaging in clinical practice: How can CT scans provide new insights into asthma care? Speakers Mario Castro, University of Kansas School of Medicine, United States Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States Disclaimers: ·      This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ·      The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program ·      The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits ·      See full US Prescribing Information for dupilumab ·      MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026 Speaker disclosures: ·      MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics. ·      NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK. References: 1.        Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.

Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care.  Uncover: ·      The importance of patient phenotyping: How can biomarkers and imaging improve asthma management? ·      Mucus plugging and airflow obstruction: What does the latest research reveal? ·      Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling? ·      The role of imaging in clinical practice: How can CT scans provide new insights into asthma care? Speakers Mario Castro, University of Kansas School of Medicine, United States Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States Disclaimers: ·      This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ·      The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program ·      The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits ·      See full US Prescribing Information for dupilumab ·      MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026 Speaker disclosures: ·      MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics. ·      NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK. References: 1.        Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.

The researchers say that the one-time therapy gives a working copy of that gene to the inner ear during a medical operation. Most of the children were treated in one ear, although one child in the two-person study was treated in both ears.研究人员说，一次性疗法在医疗操作过程中将该基因的工作副本赋予了内耳。 尽管两人的研究中的一个孩子在两个耳朵中都接受了治疗，但大多数孩子都被一只耳朵接受治疗。The study with six children took place at Fudan University in Shanghai. Dr. Yilai Shu helped lead the study and trained in Chen's laboratory. Chen was involved in the research. Chinese science organizations and biotechnology company Shanghai Refreshgene Therapeutics helped provide financial support. 与六个孩子的研究在上海的福丹大学进行。 Yilai Shu博士帮助领导了这项研究，并接受了Chen的实验室的培训。 陈参与了研究。 中国科学组织和生物技术公司上海刷新的治疗学有助于提供财务支持。Researchers observed the children for about six months. They do not know why the treatment did not work in one of them. But the five others, who were completely deaf, can now hear a normal discussion, the researchers said. 研究人员观察到孩子大约六个月。 他们不知道为什么治疗在其中一种中没有起作用。 研究人员说，但是五个完全聋哑的五个人现在可以听到正常的讨论。 Chen estimated they now hear at a level 60 percent to 70 percent of normal. The therapy caused no major side effects. 陈估计他们现在听到的是正常水平的60％至70％。 该疗法没有引起重大副作用。Early results from other research have shown similar results. 其他研究的早期结果显示出相似的结果。Regeneron Pharmaceuticals is a biotech company based in New York state. It announced in October that a child under two years old showed improvements six weeks after gene therapy. The results came from a study Regeneron did with support from Decibel Therapeutics, a company in Boston. Regeneron Pharmaceuticals是一家位于纽约州的生物技术公司。 它在十月份宣布，两岁以下的儿童在基因治疗六周后表现出改善。 结果来自Regeneron在波士顿公司的Decibel Therapeutics的支持下进行的研究。 Columbia University's Dr. Lawrence Lustig is involved in the Regeneron study. He said although the children in these studies do not end up with very good hearing, “even a moderate hearing loss recovery in these kids is pretty astounding.” 哥伦比亚大学的劳伦斯·卢斯蒂格（Lawrence Lustig）博士参与了Regeneron研究。 他说，尽管这些研究中的孩子们并没有听到很好的听力，但“即使这些孩子的听力损失恢复也令人震惊。” He added that many questions remain. They include how long the therapies will last and if hearing will continue to improve in the children. 他补充说，仍然存在许多问题。 它们包括疗法将持续多长时间，以及儿童的听力是否会继续改善。 Some people question if gene therapy for deafness is ethical. 有些人质疑基因疗法是否对耳聋是道德的。 Teresa Blankmeyer Burke is a professor who is deaf and who deals with medical ethics. She teaches at Gallaudet University, a university for deaf people in Washington, D.C. She said that there is no agreement about the need for gene therapy targeting deafness. Teresa Blankmeyer Burke是一位聋哑人，涉及医学道德的教授。 她在华盛顿特区的聋人大学加洛德大学（Gallaudet University）教授。 She also pointed out that deafness does not cause severe or deadly illness. Blankmeyer Burke said that it is important to work with deaf community members about the importance of gene therapy. She added gene therapy is seen by many as a possible threat to “signing Deaf communities.” 她还指出，耳聋不会引起严重或致命的疾病。 布兰克迈尔·伯克（Blankmeyer Burke）说，与聋人社区成员合作有关基因疗法的重要性很重要。 她补充说，许多人认为基因疗法可能是对“签署聋人社区”的可能威胁。 However, Chen said: “This is real proof showing gene therapy is working.” And he added, “It opens up the whole field.” 但是，陈说：“这是表明基因疗法正在起作用的真正证据。” 他补充说：“这打开了整个领域。”

Comment on the Show by Sending Mark a Text Message.This episode is part of my initiative to provide access to important court decisions  impacting employees in an easy to understand conversational format using AI.  The speakers in the episode are AI generated and frankly sound great to listen to.  Enjoy!The battlefield of workplace accommodations and family caregiving responsibilities takes center stage in our detailed examination of Kemp v. Regeneron Pharmaceuticals. This landmark case illuminates the critical distinction between denying leave and subtly discouraging employees from exercising their rights under the Family and Medical Leave Act.We trace the journey of Denise Kemp, a decade-long employee with a history of promotions and positive performance, whose relationship with her employer deteriorated after seeking flexibility to care for her disabled daughter. The tension between remote work policies and leave rights creates a fascinating legal puzzle that ultimately hinged on technicalities rather than merits.The Second Circuit's ruling provides crucial clarity on what constitutes FMLA interference, establishing that employers can violate the law without ever formally denying leave requests. Yet despite this employee-friendly interpretation, procedural rules—particularly the unforgiving statute of limitations—proved decisive. We explore how timing can make or break employment claims regardless of their underlying validity.Beyond the technical legal analysis, we extract practical lessons for both sides of the employment relationship. For workers, understanding deadlines and documenting problematic interactions becomes paramount. For companies, the case serves as a warning that compliance means more than simply processing paperwork—it requires creating an environment where employees feel genuinely free to exercise their rights without subtle punishment.Have you encountered challenges balancing family care responsibilities with workplace expectations? The evolving legal landscape around remote work accommodations continues to shape both employee rights and employer obligations. Share your experiences or questions about navigating these complex waters. If you enjoyed this episode of the Employee Survival Guide please like us on Facebook, Twitter and LinkedIn. We would really appreciate if you could leave a review of this podcast on your favorite podcast player such as Apple Podcasts. Leaving a review will inform other listeners you found the content on this podcast is important in the area of employment law in the United States. For more information, please contact our employment attorneys at Carey & Associates, P.C. at 203-255-4150, www.capclaw.com.Disclaimer: For educational use only, not intended to be legal advice.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KVY865. CME/MOC/AAPA credit will be available until March 19, 2026.Mastering the Art of Referring Pediatric Patients With Eosinophilic Esophagitis to Specialty Care for Timely Treatment: Spotting the Signs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KVY865. CME/MOC/AAPA credit will be available until March 19, 2026.Mastering the Art of Referring Pediatric Patients With Eosinophilic Esophagitis to Specialty Care for Timely Treatment: Spotting the Signs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KVY865. CME/MOC/AAPA credit will be available until March 19, 2026.Mastering the Art of Referring Pediatric Patients With Eosinophilic Esophagitis to Specialty Care for Timely Treatment: Spotting the Signs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KVY865. CME/MOC/AAPA credit will be available until March 19, 2026.Mastering the Art of Referring Pediatric Patients With Eosinophilic Esophagitis to Specialty Care for Timely Treatment: Spotting the Signs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KVY865. CME/MOC/AAPA credit will be available until March 19, 2026.Mastering the Art of Referring Pediatric Patients With Eosinophilic Esophagitis to Specialty Care for Timely Treatment: Spotting the Signs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KVY865. CME/MOC/AAPA credit will be available until March 19, 2026.Mastering the Art of Referring Pediatric Patients With Eosinophilic Esophagitis to Specialty Care for Timely Treatment: Spotting the Signs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTR865. CME/MOC/AAPA credit will be available until March 10, 2026.Expert Insights on the Use of Targeted Biologic Therapy in Patients With COPD and Evidence of Type 2 Inflammation: Taking It on a Case-by-Case Basis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTR865. CME/MOC/AAPA credit will be available until March 10, 2026.Expert Insights on the Use of Targeted Biologic Therapy in Patients With COPD and Evidence of Type 2 Inflammation: Taking It on a Case-by-Case Basis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTR865. CME/MOC/AAPA credit will be available until March 10, 2026.Expert Insights on the Use of Targeted Biologic Therapy in Patients With COPD and Evidence of Type 2 Inflammation: Taking It on a Case-by-Case Basis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTR865. CME/MOC/AAPA credit will be available until March 10, 2026.Expert Insights on the Use of Targeted Biologic Therapy in Patients With COPD and Evidence of Type 2 Inflammation: Taking It on a Case-by-Case Basis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTR865. CME/MOC/AAPA credit will be available until March 10, 2026.Expert Insights on the Use of Targeted Biologic Therapy in Patients With COPD and Evidence of Type 2 Inflammation: Taking It on a Case-by-Case Basis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTR865. CME/MOC/AAPA credit will be available until March 10, 2026.Expert Insights on the Use of Targeted Biologic Therapy in Patients With COPD and Evidence of Type 2 Inflammation: Taking It on a Case-by-Case Basis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DJG865. CME credit will be available until March 3, 2026.Retinal Disease in Emergency Medicine: Timely Recognition and Referral for Specialty CareThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians and PVI, PeerView Institute for Medical Education. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DJG865. CME credit will be available until March 3, 2026.Retinal Disease in Emergency Medicine: Timely Recognition and Referral for Specialty CareThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians and PVI, PeerView Institute for Medical Education. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DJG865. CME credit will be available until March 3, 2026.Retinal Disease in Emergency Medicine: Timely Recognition and Referral for Specialty CareThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians and PVI, PeerView Institute for Medical Education. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Join Prof. Lisa Beck as she explores the chronic and persistent burden of AD as well as the concept of early intervention.   ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.   This podcast is intended for healthcare professionals only.   Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits.   Speaker disclosures: Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi.    © 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2407353  – 1.0 – 02/2025 MAT-US-2501683 v1.0 - P Expiration Date: 02/24/2027

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. A lawsuit against Merck related to the HPV vaccine Gardasil, led by Robert F. Kennedy Jr., has been suspended after confirmation. Biopharma bankruptcies are at a peak, with 14 companies filing for chapter 11 protection in 2023 and numbers remaining high in 2024. Gilead has passed on an option for a cancer drug from Arcus, and Merck has partnered with Epitopea to identify unknown tumor antigens. The American Biomanufacturing Summit is set to take place in April 2025 in San Francisco, bringing together industry leaders for exclusive sessions and networking opportunities. The pharmaceutical industry is facing challenges such as patent cliffs and regulatory changes, with companies like Exelixis looking to next-generation cancer drugs for growth. Novo is seeking $830 million in a fraud case against a Singaporean biotech company over a kidney drug. Additionally, there are insights on site survival for clinical research sites and how biotechs can avoid state and local tax surprises. Trump's administration is reportedly seeking to dismantle parts of the FDA workforce, leading to concerns about job security within the agency.Biopharma bankruptcies remained high in 2024, with 14 companies filing for chapter 11 protection, the most in over a decade. Cour Pharmaceuticals solidified its mission last year with a series a raise. Some biotechs are facing unexpected tax consequences when dealing with big pharma. Several top pharma companies are facing massive patent cliffs, including Merck's Keytruda. Novo seeks $830 million in a fraud case against a Singaporean biotech, while Exelixis looks to next-gen cancer drugs. Biogen and Stoke strike a co-development deal for Dravet syndrome. The FDA faces uncertainty as the Trump team seeks to dismantle the workforce. Aardvark Therapeutics raises $94 million for obesity treatments. Abbott, Life Edit Therapeutics, and Regeneron Pharmaceuticals are hiring for various positions.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NMD865. CME/MOC/CC/AAPA/IPCE credit will be available until February 17, 2026.Mastering the Art and Science of Biologic Therapy for CRSwNP: Who Are the Candidates and How Do You Manage Their Care? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Bristol Myers Squibb is seeking to broaden the use of its CAR T cell therapy, Breyanzi, to address marginal zone lymphoma as a strategy to offset losses from exclusivity. In other news, Boehringer Ingelheim has seen promising results in a Phase III trial for its lung fibrosis drug, randomilast, aimed at progressive pulmonary fibrosis. However, Pliant has experienced a stock decline following the halt of its Phase IIb/III study for idiopathic pulmonary fibrosis. Additionally, Vertex has received FDA approval for its non-opioid pain treatment, while AbbVie has secured approval for a new antibiotic. Bain's acquisition of Tanabe for $3.3 billion is also making headlines. Regeneron is currently in a legal battle with Sanofi over the Dupixent pact, and Equillium's itolizumab is undergoing testing against Humira for ulcerative colitis. On the horizon, Acelyrin and Alumis are joining forces to address immune-mediated diseases, while Eisai is seeking subq approval for Leqembi due to sluggish US sales. Job opportunities are available at ATCC, AbbVie, Regeneron Pharmaceuticals, and Dren Bio.

Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.

Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.

Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.